title: Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET).
abstract: BACKGROUND
  No prospective trial-based data are available for incremental cost-effectiveness of drug-eluting stents (DES) compared with bare-metal stents (BMS) in unselected patients, as treated in everyday practice.
  
  
  METHODS
  The Basel stent cost-effectiveness trial (BASKET) included 826 consecutive patients treated with angioplasty and stenting for 1281 de-novo lesions, irrespective of indication for angioplasty. Patients were randomised to one of two DES (Cypher, n=264; Taxus, n=281) or to a cobalt-chromium-based BMS (Vision, n=281) and followed up for 6 months for occurrence of major adverse cardiac events and costs. Analysis was by intention-to-treat. The primary endpoint was cost-effectiveness after 6 months, with effectiveness defined as reduction of major adverse cardiac events.
  
  
  RESULTS
  Cardiac death, myocardial infarction, or target vessel revascularisation occurred in 39 of 544 (7.2%) patients with DES and 34 of 280 (12.1%) with BMS (odds ratio 0.56, 95% CI 0.35-0.91; p=0.02), without significant differences between the two DES. Total costs at 6 months were higher with DES (mean 10,544, SD 6849) than with BMS (9639, 9067; p<0.0001); higher stent costs of DES were not compensated for by lower follow-up costs. Incremental cost-effectiveness ratio of DES compared with BMS to avoid one major event was 18,311, and costs per quality-adjusted life-year gained were more than 50 000. Subgroup analyses showed that DES were more cost-effective for elderly patients in specific high-risk groups.
  
  
  CONCLUSIONS
  In a real-world setting, use of DES in all patients is less cost effective than in studies with selected patients. Use of these stents could be restricted to patients in high-risk groups.
authors.affiliation: Division of Cardiology, University of Basel, CH-4031 Basel, Switzerland.
authors.forename: Christoph
authors.initials: C
authors.lastname: Kaiser
authors.forename: Hans Peter
authors.initials: HP
authors.lastname: Brunner-La Rocca
authors.forename: Peter T
authors.initials: PT
authors.lastname: Buser
authors.forename: Piero O
authors.initials: PO
authors.lastname: Bonetti
authors.forename: Stefan
authors.initials: S
authors.lastname: Osswald
authors.forename: André
authors.initials: A
authors.lastname: Linka
authors.forename: Alain
authors.initials: A
authors.lastname: Bernheim
authors.forename: Andreas
authors.initials: A
authors.lastname: Zutter
authors.forename: Michael
authors.initials: M
authors.lastname: Zellweger
authors.forename: Leticia
authors.initials: L
authors.lastname: Grize
authors.forename: Matthias E
authors.initials: ME
authors.lastname: Pfisterer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D002858:Chromium Alloys; D003327:Coronary Disease / Q000191:economics* / Q000628:therapy; D023903:Coronary Restenosis / Q000191:economics / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000517:prevention & control; D017239:Paclitaxel / Q000008:administration & dosage*; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents / Q000191:economics*
chemical_list: D002858:Chromium Alloys; D017239:Paclitaxel; D020123:Sirolimus